Soleno Therapeutics (NASDAQ:SLNO) traded higher on Tuesday after Betaville said in a report that the Redwood City, California ...

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” ...

FDA approval of VYKAT XR for hyperphagia in Prader-Willi Syndrome marks a major milestone for Soleno Therapeutics.

Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the 10 biotech stocks screaming a buy now. On June 17, Piper Sandler ...

Conference is the first-ever international meeting jointly hosted by the Prader-Willi Syndrome Association | USA, the ...

Soleno Therapeutics, Inc. announced its participation in the 2025 United In Hope: International Prader-Willi Syndrome Conference, scheduled for June 24-28, 2025, in Phoenix, AZ. The company will ...

Investing.com - TD Cowen initiated coverage on Soleno Therapeutics Inc. (NASDAQ:SLNO) with a buy rating and a price target of $110.00 on Monday. The company, currently valued at $4.03 billion, has ...

Soleno Therapeutics, Inc. has secured a loan and security agreement with Oxford Finance LLC for up to $200 million, aiming to enhance its financial standing for the anticipated commercial launch ...

Soleno Therapeutics stock has surged over 1,500% since September 2023, driven by the progress and today's FDA approval of Vykat for Prader-Willi syndrome, despite initial clinical trial challenges.

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) saw unusually-high trading volume on Monday after HC Wainwright raised their price target on the stock from $70.00 to $100.00.

Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome Provided by GlobeNewswire Mar 26, 2025, 9:15:58 PM.

Lifesci Capital also issued estimates for Soleno Therapeutics’ Q4 2024 earnings at ($0.37) EPS, Q1 2025 earnings at ($1.67) EPS, Q2 2025 earnings at ($1.13) EPS, Q3 2025 earnings at […] ...